

## Targretin<sup>®</sup> (bexarotene) – First-time generic

- On May 24, 2022, Amneal launched an [AB-rated](#) generic version of Bausch Health's [Targretin \(bexarotene\)](#) topical gel.
  - Amneal was awarded 180-days of Competitive Generic Therapy exclusivity.
- Targretin gel is approved for the topical treatment of cutaneous lesions in patients with cutaneous T-cell lymphoma (CTCL) (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.
- Bexarotene is also available as a generic [oral capsule](#) for the treatment of cutaneous manifestations of CTCL in patients who are refractory to at least one prior systemic therapy.